Pre-Conference Workshop Day

Workshop A | 9.00-11.00 AM

Advancing Translation of Engineered Therapeutics into the Clinic with Improved Models Demonstrating Efficacy & Safety

To move from pre-clinical to clinical development, one of the major obstacles hindering the field is the lack of translatability between in vitro methods and animal models. This workshop focuses on the main factors to accelerate the translation of your synthetic-based therapeutic. Practical examples and core challenges will be discussed.

Join this Session to:

  • Discuss the lack of translatability, with both microbial approaches and mammalian systems, between animal models and humans
  • Highlight the challenges encountered when translating synthetic-based products from the lab to animal models
  • Understand the potential of synthetic biology approaches in the pre-clinical stages
Wenning Qin, eGenesis

Wenning Qin
Senior Vice President, Research

Ruben Vazquez-Uribe

Ruben Vasquez-Uribe
Co-Principal Investigator
of the Bacterial Synthetic
Biology Section
The Novo Nordisk
Foundation Center for
Bio Sustainability

Workshop B | 11.30-1.30 PM

Diversity, Equity & Inclusion (DEI) Workshop Led by Hosting Partner, Synthego

Session details to be revealed


Workshop C | 2.30-4.30 PM

Accelerating Synthetic Biology-Based Therapeutics into the Clinic with Early Analytics

Early investment in a robust set of assays and in-process development is key to successful regulatory submissions, and the translation of a well defined product into the clinic. With a focus on analytical development, this workshop will help expedite the clinical adoption of your engineered therapeutic. Attendees of this session will be encouraged to take part in a discussion around published examples of assays used for product characterization.

Join this Session to:

  • Discuss the lack of translatability: how can best-in-class analytics be used to fast-track products into the clinic?
  • Understand the robustness and stability of your synthetic product to demonstrate translatability and demonstrate safety, efficacy, and quality of your therapeutic product
  • Learn more about the general analytical challenges for live bacterial
Jonathan Winkler, Seres Therapeutics

Jonathan Winkler
Senior Director, Analytical Development
Seres Therapeutics

Anders Lund, Synlogic Therapeutics

Anders Lund
Head of Analytical Development